The China-based immuno-oncology company, backed by Merck & Co since 2011, floated at the top of it range and has gained since its debut yesterday.
BeiGene, a China-based biopharmaceutical company that counts pharmaceutical firm Merck & Co among its investors, went public in the US yesterday, floating in a $158.4m initial public offering.
A total of 6.6 million American Depositary Shares, each representing 13 normal shares, were issued, priced at $24.00 each, the top of the $22 to $24 range set by the company.
BeiGene is developing immuno-oncology drugs, and will invest $79m of the proceeds in advancing its drug pipeline through the dose-escalation…
